FAQ: Voyageur Pharmaceuticals' Board Expansion with Virginia Alling
TL;DR
Voyageur Pharmaceuticals strengthens its board with Wall Street veteran Virginia Alling to accelerate U.S. market access and unlock institutional investment for competitive advantage.
Voyageur appoints Virginia Alling to its board, leveraging her 30 years of capital markets expertise to systematically expand U.S. operations and secure regulatory approvals.
Voyageur's enhanced board leadership aims to improve healthcare by developing higher quality medical imaging contrast agents for better patient diagnostics.
Voyageur Pharmaceuticals is pioneering vertically integrated contrast media production from natural barium sources, potentially revolutionizing medical imaging quality.
Found this article helpful?
Share it with your network and spread the knowledge!
Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director to strengthen its board of directors, subject to regulatory approval.
Virginia Alling is a seasoned financial executive with over 30 years of experience in corporate banking, capital markets, and strategic advisory. She currently serves as Senior Vice President & Managing Director at PNC Bank and has previously worked at JPMorgan Chase and Wells Fargo.
Her expertise in U.S. public offerings, M&A, revenue optimization, and cross-border financing will help unlock institutional U.S. investment and streamline Voyageur's US market entry for its pharmaceutical-grade barium and iodine products.
Voyageur has recently enhanced its board with Wall Street veterans Jeffrey J. Kraws and Christopher A. Van Buren, building a high-caliber team with proven Wall Street acumen.
Voyageur is a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, with a strategic focus on vertically integrating the barium and iodine contrast markets.
The company plans to generate sales by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring validation of its products by regulatory agencies worldwide.
She has deep experience in M&A, IPOs, ESOPs, leveraged finance, revenue optimization, and guiding private equity-backed and family-owned businesses through capital structure solutions and succession planning.
The company is focused on FDA approvals for its barium contrast products, scaling its Oklahoma iodine operations, and pursuing development of new endo fullerene drugs.
Voyageur trades under the symbol VM on the TSX Venture Exchange and VYYRF on the OTC market.
The appointments underscore Voyageur's commitment to assembling a high-caliber board with proven Wall Street expertise to facilitate U.S. market expansion, capital market access, and strategic growth for the company.
Curated from NewMediaWire
